HealthTech company focused on early detection of breast cancer, Volpara Health (ASX: VHT), has reported a fourth consecutive positive net…
According to the US Food and Drug Administration (FDA), Precision Medicine, or “personalised medicine”, is a new way of tailoring…
In 2023, the emerging cancer diagnostics market is estimated to be valued at over $23 billion. Everything is fair game…
As diseases continue to adapt, the realm of medical diagnostics must intelligently progress to adeptly combat these changes. Timely interventions…
Precision diagnostics company INOVIQ (ASX: IIQ) has achieved noteworthy results from an independent clinical validation study of its SubB2M/CA15-3 test…
Cash, it's the lifeblood of any business and while their specialty in early stage disease diagnosis, Lumos Diagnostics (ASX: LDX)…